Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan
Main finding · Insulin initiationResult — go to the resultHazard ratio 0.46 95% CI 0.28–0.74Authors' conclusion
The risk of insulin initiation was lower in patients with T2DM newly treated with an SGLT2i than in those newly treated with a DPP4i. SGLT2i may reduce or delay the need for insulin therapy.
Study context
- Population
- Japanese patients with T2D newly treated with an SGLT2i or a DPP4i, JMDC Claims Database, 1 January 2015–31 March 2023matched cohort
- Participants
- 18,488 vs 18,488
- Exposure
- New SGLT2i vs new DPP4i
- SGLT2in = 18,488
- DPP4in = 18,488reference
- Outcome
- Insulin initiation
Methodological detailspropensity-score matched 1:1, claims database (JMDC)
- Propensity-score matched 1:1
- Claims database (JMDC)
Main finding
As reported in the abstract
Hazard ratio
0.46
95% CI 0.28–0.74
P = 0.001
By group
SGLT2i
0.95 per 1000 person-years
DPP4i
2.12 per 1000 person-years
SGLT2ivs DPP4i
HR 0.46 (95% CI 0.28–0.74); P = 0.001
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Other antidiabetic drugs added onto baseline treatment | 0.66 (0.64–0.69) | P < 0.001 | |
| Antihypertensive drugs added onto baseline treatment | 0.90 (0.85–0.95) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Original publication
Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan. Diabetes Obes Metab. Published 13 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →